eligibility_summary
Eligibility: Adults ≥18 with relapsed/refractory multiple myeloma after ≥2 cycles including IMiD, PI, and anti‑CD38, measurable disease, ECOG 0–2, LVEF ≥45%, adequate ECG and organ function, contraception required. Exclude: elotuzumab allergy, amyloidosis/WM/POEMS/CNS MM, recent steroids/immunosuppression, active autoimmune, infection, TB, liver disease, HIV/HBV/HCV, high bleeding risk, recent surgery/live vaccine/anti‑myeloma tx, MI/angina, other recent cancer, incarcerated, pregnant/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: SLAMF7 FPBMC (CS-1 FPBMC), an autologous cellular immunotherapy. Patient PBMCs (primarily T cells) are collected, activated ex vivo with IL-2 and OKT3 (anti-CD3 mAb), then “armed” by coating with OKT3 and elotuzumab (anti-SLAMF7/CS1 mAb) to generate bispecific antibody–armed T cells. Dosing: 8 weekly IV infusions, then 8 every 2 weeks. Mechanism of action: Elotuzumab binds SLAMF7 on myeloma cells while OKT3 engages CD3 on T cells, bridging cells to form an immune synapse and redirect T-cell cytotoxicity against SLAMF7+ multiple myeloma, IL-2 supports T-cell proliferation/activation. Targets: SLAMF7/CS1 on myeloma cells, CD3/TCR signaling on autologous T cells. Status: withdrawn (slow accrual).